These are standard post-annual-meeting governance filings with no immediate trading catalyst. The authorized share increase provides headroom for potential future capital raises or M&A but carries no current dilution. Monitor future filings for actual equity grants or any capital markets activity that would utilize the new share authorization.
Price Chart
Executive Summary
CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockholders approved a charter amendment to double authorized common shares from 300M to 600M, an amendment to the 2015 Equity Incentive Plan adding 6.5M new shares, and an amendment to the Employee Stock Purchase Plan adding 1M shares. These are routine governance and equity plan replenishments that enable future compensation grants and capital flexibility but signal no immediate operational change.
Key Facts
- Stockholders approved an amendment to the certificate of incorporation increasing authorized common shares from 300,000,000 to 600,000,000.
- Stockholders approved an amendment to the 2015 Equity Incentive Plan, increasing shares authorized for issuance by 6,500,000 shares.
- Stockholders approved an amendment to the Employee Stock Purchase Plan, increasing shares authorized for issuance by 1,000,000 shares.
- All seven proposals at the Annual Meeting were approved by stockholders; there were no contested matters or director departures.
Financial Impact
No immediate financial impact. The authorized share increase and equity plan amendments are routine enabling actions that do not trigger any cash transaction or change in reported financials.
Risk Factors
- Potential future dilution if the newly authorized shares are issued in a secondary offering or equity compensation. The share count increase from 300M to 600M authorized gives the company significant capacity for future dilution without further stockholder approval.
- The charter amendment and equity plan increases may precede future capital raises, which could pressure the stock price if executed at a discount.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-277631 |
| Document: d154321d8k.htm | 0001193125-26-277631 |
| Document: d154321dex102.htm | 0001193125-26-277631 |
| Document: d154321dex31.htm | 0001193125-26-277631 |
| Document: 0001193125-26-277631-index-headers.html | 0001193125-26-277631 |
| Document: 0001193125-26-277631-index.html | 0001193125-26-277631 |
| Document: 0001193125-26-277631.txt | 0001193125-26-277631 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 8-K | $3.15 $2.77 | ▼ −12.22% | ▼ −15.47% | $2.58 (−18.25%) |
Mar 18, 2026 28w ago | Press Release | $4.40 $2.98 | ▼ −32.27% | ▼ −43.80% | $2.58 (−41.48%) |
Mar 16, 2026 28w ago | Press Release | $5.45 $2.98 | ▲ +45.32% | ▲ +55.18% | $2.58 (+52.75%) |
Mar 16, 2026 28w ago | Press Release | $6.75 $2.94 | ▼ −56.44% | ▼ −66.93% | $2.58 (−61.85%) |
Mar 4, 2026 30w ago | Press Release | $5.07 $3.71 | ▼ −26.82% | ▼ −36.91% | $2.58 (−49.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access